 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H10BrFN4S |
| Molar mass | 377.24 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Flubrotizolam (2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine) is a thienotriazolodiazepine derivative with potent sedative and anxiolytic effects, which has been sold as a designer drug. [1] [2] [3]
Thailand's Psychotropic Substances Act is a law designed to regulate certain mind-altering drugs. According to the Office of the Narcotics Control Board, "The Act directly resulted from the Convention on Psychotropic Substances 1971 of which Thailand is a party." The Act divides psychotropic drugs into four Schedules. Offenses involving Schedule I and II drugs carry heavier penalties than those involving Schedule III and IV drugs. Note that this statute does not regulate most opioids, cocaine, or some amphetamines. The vast majority of narcotic painkillers, along with cocaine and most amphetamines are regulated under the Narcotics Act.
Brotizolam is a sedative-hypnotic thienotriazolodiazepine drug which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to other short-acting hypnotic benzodiazepines such as triazolam or midazolam. It is used in the short-term treatment of severe insomnia. Brotizolam is a highly potent and short-acting hypnotic, with a typical dose ranging from 0.125 to 0.25 milligrams, which is rapidly eliminated with an average half-life of 4.4 hours.
Phenazepam is a benzodiazepine drug, which was developed in the Soviet Union in 1975, and now produced in Russia and some affiliated countries.
Propylisopropyltryptamine (PiPT) is a chemical in the tryptamine family, which reportedly produces psychedelic and hallucinogenic effects that resemble those of other related dialkyl tryptamine derivatives, although PiPT is reportedly relatively weak and short lasting. It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.
Zapizolam is a pyridodiazepine drug, which is a benzodiazepine analog of pyridotriazolodiazepine group. It has sedative and anxiolytic effects similar to those produced by benzodiazepine derivatives, and has been sold illicitly as a designer drug.
Rilmazafone is a water-soluble prodrug developed in Japan. Once metabolized, rilmazafone is converted into several benzodiazepine metabolites that have sedative and hypnotic effects. These metabolites induce impairment of motor function and have hypnotic properties.
Nortilidine is the major active metabolite of tilidine. It is formed from tilidine by demethylation in the liver. The racemate has opioid analgesic effects roughly equivalent in potency to that of morphine. The (1R,2S) isomer has NMDA antagonist activity. The drug also acts as a dopamine reuptake inhibitor. The reversed-ester of nortilidine is also known, as is the corresponding analogue with the cyclohexene ring replaced by cyclopentane, which have almost identical properties to nortilidine.
Metizolam is a thienotriazolodiazepine that is the demethylated analogue of the closely related etizolam.
Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.
3-Chloro-PCP (3'-Cl-PCP) is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It has comparable potency to phencyclidine but with a slightly different effects profile, being somewhat more potent as an NMDA antagonist but around the same potency as a dopamine reuptake inhibitor. It was first identified in Slovenia in December 2020, and was made illegal in Hungary in April 2021.
3-Fluoro-PCP is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It was first identified in Slovenia in October 2020, and was made illegal in Hungary in April 2021.
Ro20-8552 is a benzodiazepine derivative with sedative and anxiolytic effects, which has been sold as a designer drug.
Ro09-9212 is a thienodiazepine derivative with sedative and anxiolytic effects, which has been sold as a designer drug.
Ro07-9749 is a benzodiazepine derivative with sedative and anxiolytic effects, which has been used as an internal standard in the analysis of other benzodiazepines, and also sold as a designer drug.
Fluadinazolam is a benzodiazepine derivative developed in 1973, with sedative and anxiolytic effects. It is a derivative of the never commercially marketed benzodiazepine adinazolam and has similarly been sold as a designer drug.
Fluetizolam is a thienotriazolodiazepine derivative with potent sedative and anxiolytic effects, which has been sold as a designer drug.
Ro20-8065 (8-Chloronorflurazepam) is a benzodiazepine derivative with anticonvulsant and muscle relaxant effects, which has been sold as a designer drug.
Ro07-5220 (6'-Chlorodiclazepam) is a benzodiazepine derivative with sedative, anxiolytic, anticonvulsant and muscle relaxant effects, which has been sold as a designer drug.
Pynazolam is a triazolobenzodiazepine derivative first invented in the 1970s, which has in more recent years been sold online as a designer drug. Anecdotal reports and in silico studies suggest it has relatively potent hypnotic and sedative effects. Pynazolam is a powerful serotonin releaser similar to nimetazepam which increases hypnotic activity and euphoria. Anecdotal evidence has also suggested that it's subjective effects are similar to methaqualone although unlike methaqualone, it cannot be smoked due to high melting-point.
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |
